PPT2

Summary

PPT2 (palmitoyl-protein thioesterase 2, HGNC:9326) is a protein-coding gene on chromosome 6p21.32, encoding Lysosomal thioesterase PPT2 (Q9UMR5). Catalyzes the cleavage of thioester bonds from S-palmitoyl-CoA or S-palmitoyl-N-acetylcysteamine (unbranched structures) but does not have activity against palmitoylcysteine or palmitoylated proteins, branched structures or bulky head groups.

This gene encodes a member of the palmitoyl-protein thioesterase family. The encoded glycosylated lysosomal protein has palmitoyl-CoA hydrolase activity in vitro, but does not hydrolyze palmitate from cysteine residues in proteins. Alternative splicing results in multiple transcript variants. Read-through transcription also exists between this gene and the downstream EGFL8 (EGF-like-domain, multiple 8) gene.

Source: NCBI Gene 9374 — RefSeq curated summary.

At a glance

• GWAS associations: 26
• Clinical variants (ClinVar): 34 total
• Druggable target: yes
• MANE Select transcript: NM_005155

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9326
Approved symbol	PPT2
Name	palmitoyl-protein thioesterase 2
Location	6p21.32
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000221988
Ensembl biotype	protein_coding
OMIM	603298
Entrez	9374

Gene structure

Transcript identifiers

Ensembl transcripts: 28 — 23 protein_coding, 3 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay, 1 retained_intron

ENST00000324816, ENST00000361568, ENST00000375137, ENST00000375143, ENST00000395523, ENST00000414204, ENST00000424499, ENST00000436118, ENST00000465047, ENST00000478521, ENST00000493548, ENST00000495908, ENST00000897785, ENST00000897786, ENST00000897787, ENST00000897788, ENST00000897789, ENST00000897790, ENST00000937057, ENST00000937058, ENST00000937059, ENST00000937060, ENST00000937061, ENST00000937062, ENST00000937063, ENST00000937064, ENST00000937065, ENST00000963978

RefSeq mRNA: 3 — MANE Select: NM_005155 NM_001204103, NM_005155, NM_138717

CCDS: CCDS4740, CCDS4742

Canonical transcript exons

ENST00000324816 — 9 exons

Exon	Start	End
ENSE00001700957	32162807	32163675
ENSE00003697195	32154587	32154777
ENSE00003697479	32155688	32155783
ENSE00003697608	32157637	32157720
ENSE00003702089	32155030	32155183
ENSE00003784379	32155871	32155978
ENSE00003847244	32154141	32154404
ENSE00003890867	32157840	32157924
ENSE00003894080	32162568	32162622

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 95.15.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 6.0688 / max 108.5483, expressed in 1368 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
67115	10.4936	1676
67112	5.2046	1140
67113	2.7824	1198
67114	0.8642	543

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left ovary	UBERON:0002119	95.15	gold quality
right ovary	UBERON:0002118	95.11	gold quality
ovary	UBERON:0000992	94.73	gold quality
lower esophagus mucosa	UBERON:0035834	94.18	gold quality
right hemisphere of cerebellum	UBERON:0014890	93.83	gold quality
cerebellar cortex	UBERON:0002129	93.68	gold quality
cerebellar hemisphere	UBERON:0002245	93.67	gold quality
cerebellum	UBERON:0002037	93.64	gold quality
tibial nerve	UBERON:0001323	92.42	gold quality
left uterine tube	UBERON:0001303	92.14	gold quality
endocervix	UBERON:0000458	91.74	gold quality
body of uterus	UBERON:0009853	91.65	gold quality
skin of leg	UBERON:0001511	91.54	gold quality
zone of skin	UBERON:0000014	91.12	gold quality
uterine cervix	UBERON:0000002	91.09	gold quality
esophagus mucosa	UBERON:0002469	91.05	gold quality
vagina	UBERON:0000996	90.96	gold quality
ectocervix	UBERON:0012249	90.87	gold quality
muscle layer of sigmoid colon	UBERON:0035805	90.75	gold quality
mucosa of stomach	UBERON:0001199	90.72	gold quality
metanephros cortex	UBERON:0010533	90.64	gold quality
skin of abdomen	UBERON:0001416	90.58	gold quality
myometrium	UBERON:0001296	90.55	gold quality
esophagus	UBERON:0001043	90.53	gold quality
fundus of stomach	UBERON:0001160	90.44	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	90.40	gold quality
apex of heart	UBERON:0002098	90.38	gold quality
placenta	UBERON:0001987	90.25	gold quality
right atrium auricular region	UBERON:0006631	90.21	gold quality
lower esophagus	UBERON:0013473	90.06	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-GEOD-100618	yes	111.58
E-ANND-3	yes	3.80

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): E2F1

miRNA regulators (miRDB)

79 targeting PPT2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-196A-5P	100.00	68.16	684
HSA-MIR-196B-5P	100.00	68.16	681
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-4500	99.99	72.72	2367
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784
HSA-LET-7I-5P	99.98	72.37	1788
HSA-MIR-98-5P	99.98	72.33	1787
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-LET-7D-5P	99.96	71.76	1632
HSA-MIR-4458	99.96	71.64	1650
HSA-MIR-4525	99.94	64.38	675
HSA-MIR-5010-5P	99.94	64.11	705
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-15A-5P	99.90	72.80	2787
HSA-MIR-15B-5P	99.90	72.78	2798
HSA-MIR-16-5P	99.90	72.80	2780
HSA-MIR-195-5P	99.90	72.81	2805
HSA-MIR-424-5P	99.89	71.90	2641

Literature-anchored findings (GeneRIF, showing 2)

• The crystal structure of palmitoyl protein thioesterase-2 (PPT2) reveals the basis for divergent substrate specificities of the two lysosomal thioesterases, PPT1 and PPT2. (PMID:12855696)
• We identified that PPT2 on chromosome 6p21 is associated with loss of lung function in the Korean population. (PMID:24387323)

Cross-species orthologs

9 orthologs

Organism	Symbol	Gene ID
danio_rerio	ppt2a.2	ENSDARG00000010782
danio_rerio	ppt2a.3	ENSDARG00000014208
danio_rerio	ppt2a.1	ENSDARG00000068840
danio_rerio	ppt2a.5	ENSDARG00000068846
danio_rerio	ppt2a.4	ENSDARG00000093176
danio_rerio	ppt2b	ENSDARG00000104542
mus_musculus	Ppt2	ENSMUSG00000015474
rattus_norvegicus	Ppt2	ENSRNOG00000000435
drosophila_melanogaster	Ppt2	FBGN0032358

Paralogs (2): PPT1 (ENSG00000131238), DOLPP1 (ENSG00000167130)

Protein

Protein identifiers

Lysosomal thioesterase PPT2 — Q9UMR5 (reviewed: Q9UMR5)

Alternative names: Palmitoyl-protein thioesterase 2, S-thioesterase G14

All UniProt accessions (5): Q9UMR5, A0A1U9X8D2, A2ABN6, A2ABN7, G8JLL2

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes the cleavage of thioester bonds from S-palmitoyl-CoA or S-palmitoyl-N-acetylcysteamine (unbranched structures) but does not have activity against palmitoylcysteine or palmitoylated proteins, branched structures or bulky head groups. Conversely, hydrolyzes both long and short chain fatty acyl-CoA substrate. Catalytically inactive due to lack of active site His-283.

Subcellular location. Lysosome.

Tissue specificity. Broadly expressed, with highest levels in skeletal muscle.

Similarity. Belongs to the palmitoyl-protein thioesterase family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9UMR5-1	1	yes
Q9UMR5-2	2, I
Q9UMR5-3	3

RefSeq proteins (3): NP_001191032, NP_005146, NP_619731 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002472	Palm_thioest	Family
IPR029058	AB_hydrolase_fold	Homologous_superfamily

Pfam: PF02089

Catalyzed reactions (Rhea), 2 shown:

• hexadecanoyl-CoA + H2O = hexadecanoate + CoA + H(+) (RHEA:16645)
• S-hexadecanoyl-N-acetylcysteamine + H2O = N-acetylcysteamine + hexadecanoate + H(+) (RHEA:84099)

UniProt features (49 total): helix 18, strand 7, glycosylation site 5, mutagenesis site 4, disulfide bond 3, active site 3, splice variant 2, sequence variant 2, turn 2, signal peptide 1, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
1PJA	X-RAY DIFFRACTION	2.7

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UMR5-F1	92.19	0.83

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3): 111 (nucleophile); 228; 283

Disulfide bonds (3): 109–117, 165–176, 276–296

Glycosylation sites (5): 60, 190, 206, 245, 289

Mutagenesis-validated functional residues (4):

Position	Phenotype
111	abolishes palmitoyl-coa hydrolase activity.
228	abolishes palmitoyl-coa hydrolase activity.
283	abolishes palmitoyl-coa hydrolase activity.
287	no effect palmitoyl-coa hydrolase activity.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-75105	Fatty acyl-CoA biosynthesis

MSigDB gene sets: 224 (showing top): MODULE_52, YAGI_AML_WITH_INV_16_TRANSLOCATION, GOBP_MACROMOLECULE_DEACYLATION, KEGG_LYSOSOME, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, GOBP_NUCLEOSIDE_PHOSPHATE_BIOSYNTHETIC_PROCESS, GOBP_ORGANOPHOSPHATE_BIOSYNTHETIC_PROCESS, EFC_Q6, PATIL_LIVER_CANCER, GOBP_NUCLEOBASE_CONTAINING_SMALL_MOLECULE_METABOLIC_PROCESS, MAHAJAN_RESPONSE_TO_IL1A_DN, MODULE_118, GOBP_FATTY_ACYL_COA_METABOLIC_PROCESS, MISSIAGLIA_REGULATED_BY_METHYLATION_UP, LIU_VAV3_PROSTATE_CARCINOGENESIS_DN

GO Biological Process (2): fatty-acyl-CoA biosynthetic process (GO:0046949), macromolecule depalmitoylation (GO:0098734)

GO Molecular Function (4): thiolester hydrolase activity (GO:0016790), fatty acyl-CoA hydrolase activity (GO:0047617), palmitoyl hydrolase activity (GO:0098599), hydrolase activity (GO:0016787)

GO Cellular Component (5): extracellular region (GO:0005576), lysosome (GO:0005764), lysosomal lumen (GO:0043202), extracellular exosome (GO:0070062), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Fatty acid metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
fatty-acyl-CoA metabolic process	1
acyl-CoA biosynthetic process	1
fatty acid derivative biosynthetic process	1
macromolecule deacylation	1
hydrolase activity, acting on ester bonds	1
acyl-CoA hydrolase activity	1
hydrolase activity	1
macromolecule depalmitoylation	1
catalytic activity	1
lytic vacuole	1
lysosome	1
vacuolar lumen	1
extracellular vesicle	1

Protein interactions and networks

STRING

1332 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PPT2	CLN5	O75503	758
PPT2	CLN3	Q13286	753
PPT2	CLN6	Q9NWW5	709
PPT2	GAP43	P17677	609
PPT2	SNAP25	P13795	602
PPT2	GSTCD	Q8NEC7	598
PPT2	STX1A	Q16623	586
PPT2	ABHD17A	Q96GS6	586
PPT2	AGA	P20933	585
PPT2	VAMP2	P19065	585
PPT2	SV2A	Q7L0J3	584
PPT2	PLA2G4A	P47712	576
PPT2	INTS12	Q96CB8	574
PPT2	MFSD8	Q8NHS3	558
PPT2	GAD2	Q05329	552

IntAct

15 interactions, top by confidence:

A	B	Type	Score
FBXO2	TMEM131L	psi-mi:“MI:0914”(association)	0.530
UST	GOLIM4	psi-mi:“MI:0914”(association)	0.530
CLEC12B	GXYLT2	psi-mi:“MI:0914”(association)	0.350
ANGPT4	POTEF	psi-mi:“MI:0914”(association)	0.350
CCL3	KRBA1	psi-mi:“MI:0914”(association)	0.350
RLN1	RTL8C	psi-mi:“MI:0914”(association)	0.350
IGF2R	MANBA	psi-mi:“MI:0914”(association)	0.350
TMPRSS13	TOR1A	psi-mi:“MI:0914”(association)	0.350
HPN	TOR1A	psi-mi:“MI:0914”(association)	0.350
ZNF232	ZNF197	psi-mi:“MI:0914”(association)	0.350
IDS	COCH	psi-mi:“MI:0914”(association)	0.350
CGA	TRIO	psi-mi:“MI:0914”(association)	0.350

BioGRID (57): PPT2 (Affinity Capture-MS), PPT2 (Affinity Capture-MS), PPT2 (Affinity Capture-MS), PPT2 (Affinity Capture-MS), PPT2 (Affinity Capture-MS), PPT2 (Affinity Capture-MS), PPT2 (Affinity Capture-MS), PPT2 (Affinity Capture-MS), PPT2 (Affinity Capture-MS), PPT2 (Affinity Capture-MS), PPT2 (Affinity Capture-MS), PPT2 (Affinity Capture-RNA), PPT2 (Affinity Capture-MS), PPT2 (Affinity Capture-MS), PPT2 (Affinity Capture-MS)

ESM2 similar proteins: A0A0P6JG37, A0A383ZFX3, A5A6P2, F1N2K1, F8J2D3, F8S101, G1T7U7, H0VCJ6, O45686, O77695, P08236, P68827, Q02083, Q09551, Q0P5H1, Q13510, Q17QB3, Q2KIY5, Q3TCN2, Q4QQW8, Q5KTC7, Q5R5N6, Q5R748, Q5RDY9, Q5U2V4, Q5VSG8, Q60HH4, Q642A7, Q69ZQ1, Q6NSJ0, Q6P1J0, Q6P4A8, Q6P7S1, Q6T3U3, Q6T3U4, Q6W3E9, Q6W3F0, Q75UG4, Q7Z4N8, Q8C7K6

Diamond homologs: O35448, O70489, P45479, Q1JQA0, Q20390, Q54CM0, Q6GNY7, Q6PCJ9, Q9UMR5, Q9VKH6, O88531, P45478, P50897, Q8HXW6, Q9W3C7

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

34 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	30
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1647 predictions. Top by Δscore:

Variant	Effect	Δscore
6:32149394:CGCAC:C	acceptor_gain	1.0000
6:32149395:GCAC:G	acceptor_gain	1.0000
6:32149396:CAC:C	acceptor_gain	1.0000
6:32149396:CACC:C	acceptor_gain	1.0000
6:32149397:AC:A	acceptor_gain	1.0000
6:32149397:ACCTA:A	acceptor_loss	1.0000
6:32149398:CC:C	acceptor_gain	1.0000
6:32149398:CCTA:C	acceptor_loss	1.0000
6:32149399:C:CC	acceptor_gain	1.0000
6:32149400:T:A	acceptor_loss	1.0000
6:32149402:C:CT	acceptor_gain	1.0000
6:32149403:G:T	acceptor_gain	1.0000
6:32149532:CCTAC:C	donor_loss	1.0000
6:32149533:CTA:C	donor_loss	1.0000
6:32149534:TA:T	donor_loss	1.0000
6:32149535:A:AC	donor_gain	1.0000
6:32149535:ACCT:A	donor_loss	1.0000
6:32149536:C:CC	donor_gain	1.0000
6:32149536:C:CG	donor_loss	1.0000
6:32149666:C:CT	acceptor_gain	1.0000
6:32149667:G:T	acceptor_gain	1.0000
6:32151804:TTTA:T	donor_loss	1.0000
6:32151806:TA:T	donor_loss	1.0000
6:32151807:A:T	donor_loss	1.0000
6:32151808:C:CA	donor_loss	1.0000
6:32151808:CCTGA:C	donor_gain	1.0000
6:32153632:GAGTT:G	donor_gain	1.0000
6:32153634:GTT:G	donor_gain	1.0000
6:32153637:G:GG	donor_gain	1.0000
6:32154763:G:GT	donor_gain	1.0000

AlphaMissense

1966 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:32155173:C:G	C109W	0.999
6:32155701:C:G	C117W	0.999
6:32155964:G:A	C176Y	0.999
6:32155974:G:C	W179C	0.999
6:32155974:G:T	W179C	0.999
6:32155172:G:A	C109Y	0.998
6:32155178:C:T	S111L	0.998
6:32155699:T:C	C117R	0.998
6:32155700:G:A	C117Y	0.998
6:32155930:T:C	C165R	0.998
6:32155931:G:A	C165Y	0.998
6:32155932:C:G	C165W	0.998
6:32155963:T:C	C176R	0.998
6:32155972:T:A	W179R	0.998
6:32155972:T:C	W179R	0.998
6:32157897:A:T	D228V	0.998
6:32157921:C:T	S236F	0.998
6:32154724:G:T	G44W	0.997
6:32154725:G:A	G44E	0.997
6:32155171:T:C	C109R	0.997
6:32155177:T:C	S111P	0.997
6:32155183:G:T	G113W	0.997
6:32155771:G:A	G141R	0.997
6:32155771:G:C	G141R	0.997
6:32155965:C:G	C176W	0.997
6:32157896:G:C	D228H	0.997
6:32154725:G:T	G44V	0.996
6:32155081:A:C	S79R	0.996
6:32155083:C:A	S79R	0.996
6:32155083:C:G	S79R	0.996

dbSNP variants (sampled 300 via entrez): RS1000407887 (6:32159999 C>G,T), RS1000918959 (6:32163153 C>A), RS1000940084 (6:32151594 T>C,G), RS1001259119 (6:32155260 C>A,T), RS1001609327 (6:32156068 T>C), RS1001946289 (6:32153513 T>A,G), RS1002050870 (6:32161811 T>C), RS1002083395 (6:32161438 C>T), RS1002397740 (6:32153171 T>G), RS1002422716 (6:32162700 G>A), RS1002581197 (6:32160468 C>T), RS1002690219 (6:32153471 G>A), RS1002707732 (6:32160765 G>A), RS1002892610 (6:32157773 A>G), RS1003334131 (6:32157382 T>G)

Disease associations

OMIM: gene MIM:603298 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

26 associations (top):

Study	Trait	p-value
GCST000542_3	Pulmonary function	3.000000e-14
GCST001834_3	Oleic acid (18:1n-9) levels	1.000000e-06
GCST001942_21	Prostate cancer	5.000000e-09
GCST002448_2	Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid)	6.000000e-06
GCST002915_5	Asparaginase hypersensitivity in acute lymphoblastic leukemia	4.000000e-06
GCST004131_25	Inflammatory bowel disease	2.000000e-31
GCST004133_79	Ulcerative colitis	5.000000e-65
GCST004521_114	Autism spectrum disorder or schizophrenia	3.000000e-17
GCST004521_117	Autism spectrum disorder or schizophrenia	3.000000e-15
GCST004521_118	Autism spectrum disorder or schizophrenia	3.000000e-15
GCST004521_126	Autism spectrum disorder or schizophrenia	2.000000e-10
GCST004521_154	Autism spectrum disorder or schizophrenia	3.000000e-08
GCST004521_17	Autism spectrum disorder or schizophrenia	2.000000e-12
GCST004521_170	Autism spectrum disorder or schizophrenia	4.000000e-14
GCST004521_173	Autism spectrum disorder or schizophrenia	4.000000e-14
GCST004521_209	Autism spectrum disorder or schizophrenia	5.000000e-16
GCST004521_211	Autism spectrum disorder or schizophrenia	5.000000e-15
GCST004521_213	Autism spectrum disorder or schizophrenia	5.000000e-13
GCST004521_226	Autism spectrum disorder or schizophrenia	4.000000e-12
GCST004521_276	Autism spectrum disorder or schizophrenia	5.000000e-10
GCST004521_296	Autism spectrum disorder or schizophrenia	6.000000e-18
GCST004521_45	Autism spectrum disorder or schizophrenia	2.000000e-16
GCST004521_81	Autism spectrum disorder or schizophrenia	1.000000e-14
GCST007325_140	General risk tolerance (MTAG)	1.000000e-10
GCST008362_153	Birth weight	3.000000e-09
GCST008363_48	Offspring birth weight	2.000000e-06

EFO canonical traits (7, from GWAS)

EFO ID	Trait name
EFO:0003892	pulmonary function measurement
EFO:0004713	FEV/FVC ratio
EFO:0005680	omega-6 polyunsaturated fatty acid measurement
EFO:0004881	asparaginase hypersensitivity
EFO:0008579	risk-taking behaviour
EFO:0004344	birth weight
EFO:0005939	parental genotype effect measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2189137 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

23 total (human), top 23 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression, decreases methylation	2
bisphenol S	decreases methylation, affects cotreatment, decreases expression	2
Doxorubicin	affects expression, increases expression	2
beta-lapachone	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
perfluorooctane sulfonic acid	increases expression	1
abrine	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Arsenic	affects methylation	1
Benzo(a)pyrene	affects methylation	1
Cisplatin	increases expression	1
Cytarabine	decreases expression	1
Dichlorodiphenyl Dichloroethylene	decreases expression	1
Dexamethasone	affects cotreatment, decreases expression	1
Indomethacin	decreases expression, affects cotreatment	1
Mercury	decreases expression	1
Ouabain	decreases expression	1
Smoke	decreases expression	1
Tobacco Smoke Pollution	affects expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, decreases expression	1
Mifepristone	increases expression	1
Cyclosporine	decreases expression	1
Particulate Matter	decreases expression, increases abundance	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL2209149	Binding	Inhibition of PPT2 binding to FP-biotin in [12C][14N]-lysine, arginine and [13C6][15N2]-lysine, arginine labeled HEK293T cells at 20 uM after 1 hr by isotopic activity-based protein profiling-MudPIT assay	Discovery and optimization of sulfonyl acrylonitriles as selective, covalent inhibitors of protein phosphatase methylesterase-1. — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.